Axios’ Erin Brodwin published a new investigation which found health care automation startup Olive is exaggerating its capabilities and only utilizes “rough estimations” to gauge its price tag cost savings. According to the report, Olive, which guarantees wellness devices charge financial savings, is only monitoring discounts if a customer requests it. The report also highlighted Olive employees’ worries about how the corporation handles patient overall health information.
This report arrives fewer than a 12 months following the company shut a whopping $400 million financial commitment spherical, which introduced its valuation to $4 billion.
Digital therapeutic company Happify launched benefits of its serious-entire world psoriasis details analysis. Scientists found that patients with psoriasis who concluded 16 Happify actions inside of a least of six weeks documented a 27% reduction in panic symptoms and a 27% improve in subjective wellbeing.
In the meantime, the study studies that individuals who concluded significantly less than 16 things to do enhanced their wellbeing score by 4.11% and reduced their nervousness rating by 8.15%.
The analysis was done by Happify Health and fitness and is not however posted in an tutorial journal.
Oura, maker of a ring health and fitness-monitoring wearable, announced before this 7 days its valuation experienced attained $2.55 billion.
Though the firm did not launch more specifics, a spokesperson told MobiHealthNews it had lifted an “oversubscribed” funding spherical. Oura mentioned the new financial commitment will go towards investigate and growth, personalized material and products innovation.
The startup most recently scooped up $100 million in Collection C funding in May 2021.
Oura discovered its Oura Ring Generation 3 in Oct. The wearable maker mentioned work out coronary heart amount monitoring, blood-oxygen sensing and an enhanced rest algorithm will be extra to the new wearable later in 2022.
Electronic pharmacy and telehealth startup Truepill is partnering with COVID-19 tests organization Curative to supply individuals obtain to Truepill’s COVID-19 digital treatment platform.
When a buyer exams beneficial at a single of Curative’s tests websites, they can obtain telehealth consults and antiviral drugs through the platform if qualified. Truepill declared its COVID-19-focused digital care offering in early December.
This isn’t Truepill’s only virtual resource aimed at managing the pandemic. In January, it introduced a test protection platform to support payers in creating their have immediate-to-client exam-buying sites, with Truepill fulfilling and shipping orders. In March 2021, the firm rolled out a suite of diagnostics, medication delivery and speak to-tracing instruments for the employer market place.
“Obtain, velocity and scale are important to any COVID-19 response, and this is in particular true when it arrives to the distribution of antiviral medications,” Truepill CEO and cofounder Sid Viswanathan reported in a assertion.
“We are thrilled to spouse with diagnostic screening chief Healing to offer an end-to-close, white-labeled digital treatment knowledge that permits productive, streamlined obtain to cure.”